Summary
BioSig is “a commercial stage medical device company that has developed a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Their initial emphasis is on providing intracardiac signal information to electrophysiologists during electrophysiology (“EP”) studies and cardiac catheter ablation procedures for atrial fibrillation (“Afib” or “AF”) and ventricular tachycardia (“VT”). Cardiac catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue in order to correct heart rhythm disturbances”.
Current Coverage
- BioSig Research Update 01.04.22
- BioSig Research Update 12.09.21
- BioSig Allocation Upgrade 04.19.21
- BioSig Research Update 12.11.20 NWM
- BioSig Allocation Increase and Target Decrease 11.20.20.NMW
- BioSig Allocation Decrease 05.14.20.NWM
- BioSig General Update 04.07.20.NWM
- BioSig Initiating Coverage 04.03.20.NWM.VL